Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 60

1.

Metabolic abnormalities associated with HIV infection and antiretroviral therapy.

Fichtenbaum CJ.

Curr Infect Dis Rep. 2009 Jan;11(1):84-92.

PMID:
19094829
2.

Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel.

Schambelan M, Benson CA, Carr A, Currier JS, Dubé MP, Gerber JG, Grinspoon SK, Grunfeld C, Kotler DP, Mulligan K, Powderly WG, Saag MS; International AIDS Society-USA.

J Acquir Immune Defic Syndr. 2002 Nov 1;31(3):257-75. Review.

PMID:
12439201
3.

Emerging drug toxicities of highly active antiretroviral therapy for human immunodeficiency virus (HIV) infection.

Heath KV, Montaner JS, Bondy G, Singer J, O'Shaughnessy MV, Hogg RS.

Curr Drug Targets. 2003 Jan;4(1):13-22. Review.

PMID:
12528986
4.
5.

[HIV infection, antiretroviral therapy, and endothelium].

Hürlimann D, Weber R, Enseleit F, Lüscher TF.

Herz. 2005 Sep;30(6):472-80. Review. German.

PMID:
16170677
6.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
7.

[Metabolic syndrome and hyperlipidemia in HIV-positive patients].

Behrens GM.

Herz. 2005 Sep;30(6):458-66. German.

PMID:
16170675
8.

Guidelines for using antiretroviral agents among HIV-infected adults and adolescents.

Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK; Panel on Clinical Practices for Treatment of HIV.

Ann Intern Med. 2002 Sep 3;137(5 Pt 2):381-433.

PMID:
12617573
9.

Metabolic complications associated with HIV protease inhibitor therapy.

Nolan D.

Drugs. 2003;63(23):2555-74. Review.

PMID:
14636077
10.

HIV and HIV treatment: effects on fats, glucose and lipids.

Gkrania-Klotsas E, Klotsas AE.

Br Med Bull. 2007;84:49-68. Epub 2007 Nov 2. Review.

PMID:
17981955
12.

Antiretroviral therapy: an update for the non-AIDS specialist.

Kalkut G.

Curr Opin Oncol. 2005 Sep;17(5):479-84. Review.

PMID:
16093800
13.

Didanosine enteric-coated capsule: current role in patients with HIV-1 infection.

Moreno S, Hernández B, Dronda F.

Drugs. 2007;67(10):1441-62. Review.

PMID:
17600392
14.

HIV and antiretroviral therapy: lipid abnormalities and associated cardiovascular risk in HIV-infected patients.

Kotler DP.

J Acquir Immune Defic Syndr. 2008 Sep 1;49 Suppl 2:S79-85. doi: 10.1097/QAI.0b013e318186519c. Review.

PMID:
18725816
15.

A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.

García F, Romeu J, Grau I, Sambeat MA, Dalmau D, Knobel H, Gomez-Sirvent JL, Arrizabalaga J, Cruceta A, Clotet BG, Podzamczer D, Pumarola T, Gallart T, O'Brien WA, Miró JM, Gatell JM.

AIDS. 1999 Dec 3;13(17):2377-88.

PMID:
10597779
16.
17.

Metabolic complications of antiretroviral therapy.

Sweet DE.

Top HIV Med. 2005 Jun-Jul;13(2):70-4. Review.

18.

Diagnosis and management of common chronic metabolic complications in HIV-infected patients.

Bader MS, Kelly DV.

Postgrad Med. 2008 Nov;120(4):17-27. doi: 10.3810/pgm.2008.11.1930. Review.

PMID:
19020362
19.
20.

The metabolic puzzle during the evolution of HIV infection.

Salas-Salvadó J, García-Lorda P.

Clin Nutr. 2001 Oct;20(5):379-91. Review.

PMID:
11534932

Supplemental Content

Support Center